|
MechanismDMD gene modulators |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1, Multicenter, Open-label Study to Investigate the Safety and Biodistribution of a Single Intrathecal Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (The ASCEND Study)
The primary objective of this study is to evaluate the safety and tolerability of a single dose of INS1201 via IT administration in ambulatory male participants with DMD.
100 Clinical Results associated with Insmed Gene Therapy LLC
0 Patents (Medical) associated with Insmed Gene Therapy LLC
100 Deals associated with Insmed Gene Therapy LLC
100 Translational Medicine associated with Insmed Gene Therapy LLC